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RESEARCH ARTICLE
Sulforaphane Inhibits Growth of Human Breast Cancer Cells
and Augments the Therapeutic Index of the Chemotherapeutic
Drug, Gemcitabine
Arif Hussain1, Javeria Mohsin1, Sathyen Alwin Prabhu1, Salema Begum1, Qurrat
El-Ain Nusri1, Geetganga Harish1, Elham Javed1, Munawwar Ali Khan2, Chhavi
Sharma1*
Abstract
Phytochemicals are among the natural chemopreventive agents with most potential for delaying, blocking or
reversing the initiation and promotional events of carcinogenesis. They therefore offer cancer treatment strategies
to reduce cancer related death. One such promising chemopreventive agent which has attracted considerable
attention is sulforaphane (SFN), which exhibits anti-cancer, anti-diabetic, and anti-microbial properties. The
present study was undertaken to assess effect of SFN alone and in combination with a chemotherapeutic agent,
gemcitabine, on the proliferative potential of MCF-7 cells by cell viability assay and authenticated the results
by nuclear morphological examination. Further we analyzed the modulation of expression of Bcl-2 and COX-2
on treatment of these cells with SFN by RT-PCR. SFN showed cytotoxic effects on MCF-7 cells in a dose- and
time-dependent manner via an apoptotic mode of cell death. In addition, a combinational treatment of SFN
and gemcitabine on MCF-7 cells resulted in growth inhibition in a synergistic manner with a combination index
(CI)<1. Notably, SFN was found to significantly downregulate the expression of Bcl-2, an anti-apoptotic gene, and
COX-2, a gene involved in inflammation, in a time-dependent manner. These results indicate that SFN induces
apoptosis and anti-inflammatory effects on MCF-7 cells via downregulation of Bcl-2 and COX-2 respectively.
The combination of SFN and gemcitabine may potentiate the efficacy of gemcitabine and minimize the toxicity
to normal cells. Taken together, SFN may be a potent anti-cancer agent for breast cancer treatment.
Keywords: Sulforaphane - gemcitabine - chemoprevention - apoptosis - breast cancer
Asian Pac J Cancer Prev, 14 (10), 5855-5860

Introduction
Despite rapid advances in diagnosis and prognosis
of breast cancer, it still remains the most common
malignancy among women worldwide (Youlden et al.,
2012). Several modifiable and non-modifiable risk factors
have been associated with the incidence of breast cancer
thereby providing compelling basis for development of
breast cancer prevention and treatment strategies. The
purpose of such strategies should be inhibition or reversal
of breast carcinogenesis while producing minimal to no
side effects, consequently targeting even the asymptomatic
women (Gabriel and Jatoi, 2012).
Sulforaphane (SFN), a dietary component found in
abundance in many cruciferous vegetables including
broccoli, cabbage and cauliflower, is one such widely
studied agent. Its chemopreventive effects have assigned
to multiple mechanisms such as modulatory action on

phase 2 enzymes via Keap1-Nrf2 signaling and antioxidant
response element (ARE)-driven gene expression as well
as by induction of cell cycle arrest and apoptosis and
inhibition of histone deacetylase (HDAC) (Clarke el al.,
2011; Rajendran et al., 2011). Conspicuously, SFN has
been shown to selectively target the precancerous and
cancerous cells (Clarke el al., 2011).
In order to avoid the complications associated with
standard cancer treatments for instance chemotherapy,
combinational treatment strategies involving
chemopreventive agents have been proposed for achieving
a therapeutic synergy between individual drugs, while
minimizing systemic toxicity caused by these therapies
(Notarbartolo, 2005; Kumi-Diaka et al., 2010; Doudican et
al., 2012). The present study was undertaken to analyze the
chemopreventive activity of SFN alone and its interaction
with a chemotherapeutic drug, gemcitabine on human
breast cell line (MCF-7).
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Materials and Methods
Cell culture
The human breast cancer cell line, MCF-7 was kindly
gifted by Dr. Tahir A Rizvi, Department of Microbiology
and Immunology, Faculty of Medicine and Health Science,
UAE University, Al-Ain, United Arab Emirates. It was
maintained in DMEM (Sigma, USA) supplemented with
10% fetal bovine serum (FBS) (Sigma, USA) and 100X
Pen-strep (Sigma, USA) in a humidified atmosphere of
5%CO2 in air at 37°C.
Preparation of drug solutions
SFN was purchased from Sigma (Sigma Aldrich,
U.S.A.). A stock solution of 10 mM SFN was prepared in
DMSO (Sigma, USA). The solution was stored in aliquots
at -20°C. Further dilutions were made in complete medium
to required concentrations between 0.01-75 µM for the
treatment of MCF-7 cells.
A stock solution of gemcitabine (Intas
Biopharmaceuticals, India) at a concentration of 133
mM (40 mg/ml) was prepared in DMSO (Sigma, USA)
and further dilutions were made in complete medium at
concentrations of 0.1-100 mM.
Cell viability assay
The antiproliferative activity of sulforaphane (0.0175µM) or gemcitabine (0.1-100 mM) and combinations
of both was evaluated on MCF-7 cells by using MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay, as previously described (Hussain et al.,
2012). Briefly, ~8000 cells/well are plated in 96 well
plates and allowed to grow for 24h in complete medium
at 37°C in order to obtain semi-confluent cultures. This
was followed by treatment with varying concentrations
of sulforaphane or gemcitabine at 24 and 48h and the
effect of combination of SFN and gemcitabine treatment
was analysed at 24h. After appropriate incubation, MTT
(Sigma, USA) (final concentration 0.5 mg/ml) was added
to each well and further incubated for 2-4h at 37°C.
Thereafter, DMSO was added to dissolve the formazan
crystals and absorbance was read at 570 nm using an
Absorbance Microplate Reader (BioTek, USA). Cell
viability was calculated as percent of control (untreated
cells), and averaged from three independent experiments.
Calculation of combination effects of SFN and gemcitabine
Combination index (CI), which provides qualitative
information on the nature of drug interaction, was
determined as described previously by Chou and Talalay
(Chou and Talalay, 1984). A CI <, =, or >1 represent
synergy, additivity, and antagonism of SFN and
gemcitabine, respectively.
Morphological analysis of MCF-7cells before and after
treatment with SFN
Morphological changes in MCF-7 cells elicited by
sulforaphane were documented using normal inverted
microscope (Labomed, USA). MCF-7 cells were treated
at a concentration of 25 µM for 24 h. Comparison of SFN
treated cells were made with the untreated cells.
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Nuclear morphological analysis of MCF-7 cells treated
with sulforaphane
The nuclear morphological changes associated with
cells undergoing apoptosis were studied using propidium
iodide (PI) staining after the treatment with sulforaphane
for different time intervals (0, 6 and 24 h). Briefly, cells
(~106 Cells/ml) were seeded on glass coverslips and left
overnight to attach in complete medium at 37 °C, followed
by treatment with 25 µM SFN for varying time points (0,
6 and 24 h). After treatment with SFN, cells were fixed
in a mixture of acetone: methanol (1:1) at −20°C for 10
min washed with 15 PBS (pH 7.4) twice and stained with
propidium iodide (10 µg/ml in PBS) for 30 s in dark at
room temperature. The coverslips were thoroughly washed
with PBS and placed upturned onto a glass slide with
mounting media (DPX). Slides were viewed at 515nm
under the Progress Fluorescent Microscope (Olympus,
USA). The images were captured at 405 magnification.
Expression analysis of Bcl-2 and COX-2 by RT-PCR
Reverse transcription-PCR was used to detect
transcriptional regulation of Bcl-2 and COX-2 in response
to treatment with 25 µM SFN. Total RNA extraction from
untreated and SFN-treated MCF-7 cells was carried out as
per the manufacturer’s instructions (GenElute Mammalian
Genomic Total RNA Kit, Sigma, USA) at various time
intervals (6, 24 and 48h). Further, total RNA was subjected
to first strand synthesis as per manufacturer’s protocol
(ProtoScript M-MuLV Taq RT-PCR Kit, New England
Biolabs, USA) followed by PCR using gene-specific
primers for β-actin, Bcl-2 and COX-2 (Bondesen et
al., 2004; Wang et al., 2005). The PCR cycle was as
follows: initial denaturation at 95°C for 5 min, followed
by 35 amplification cycles (denaturation at 94°C for 30s,
annealing at 55°C for 30s, and extension at 72°C for 45s),
with final extension at 72°C for 7 min. Amplified products
were visualized on a 2% agarose gel containing ethidium
bromide. β actin was taken as an internal control.
Statistical analysis
qAll data are expressed as means±SD of at least 3
experiments. Fisher’s exact test was adopted for statistical
evaluation of the results. Significant differences were
established at p<0.05.

Results
Cell growth inhibitory effect of SFN and gemcitabine on
human breast cancer cells, MCF-7
The effect of SFN on cell growth of human breast
cancer cells, MCF-7 was determined by treating the
cells with varying concentrations of SFN (0.01-75μM)
for 24h and 48h respectively. Treatment with increasing
concentrations of SFN (0.01-75μM) resulted in inhibition
of cell growth in a dose and time-dependent manner
compared with the untreated controls (Figure 1). SFN
at a dose of 25μM for 24h and 20µM at 48h induced
approximately 50% decrease in cell viability (EC50) in
MCF-7 cells (Figure 1). The experiment was repeated at
least three times.
MCF-7 cells showed growth inhibition in a dose- and
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Figure 3. SFN Treatment Induces Nuclear
Morphological Changes in MCF-7 Cells. A) Untreated
MCF-7 cells show large and prominent nuclei; (B) and (C)

30	
  
20	
  
10	
  
0	
  

0.01	
  

0.1	
  

1	
  

5	
  

10	
  

15	
  

20	
  

25	
  

30	
  

40	
  

50	
  

75	
  

SFN Concentration (µM)

Figure 1. Effect of SFN on MCF-7 Cells. SFN treatment

at varying concentrations (0.01-75μM) result in dose and time
dependent growth inhibition of MCF-7 Cells at 24 and 48h time
intervals. EC50 of Sulforaphane was found to be 25μM at 24h
and 20µM at 48h. Values are means±SD of three independent
experiments. Each value with SFN treatment differs from the
control value (p<0.05)

On treatment with 25μM SFN for 6 and 24 h respectively, the
nuclei of these cells showed various characteristics associated
with apoptosis such as nuclear condensation and fragmentation
(white arrow), apoptotic bodies (yellow arrow) and nuclear
blebbing (orange arrows) which accumulated with increased
time of exposure. (Magnification 4005)
100	
  
90	
  

24	
  h	
  

80	
  

48	
  h	
  

Cell viability (%)

70	
  
60	
  
50	
  
40	
  
30	
  
20	
  
10	
  

A

B

Figure 2. SFN may Induce Cell Death in MCF-7 Cells
via Apoptosis. A) Microscopic examination of untreated MCF7 cells showed their proper morphological characteristics; B)

After exposure of MCF-7 cells to 25 µM SFN for 24h, typical
rounding off of these cells was observed which is a feature of
cell death through the apoptotic pathway (Magnification 1005)

time-dependent manner (Figure 4) when treated with
gemcitabine at concentrations ranging from 0.1-100 mM
for 24 and 48 h. The EC50 value was found to be 35mM
and 1mM for 24 and 48 h respectively.
Morphological studies of SFN treated human breast
cancer Cell line, MCF-7
Morphological changes in MCF-7 cells elicit by
SFN treatement were documented using normal inverted
microscope. A charateristic indicator of cell death,
rounding off of cells, was observed in 25µM SFN treated
MCF-7 cells for 24 h as compared to untreated cells which
showed proper morphology of attached healthy cells.
This indicates that the cell death induced by SFN may be
through the apoptotic pathway (Figure 2).
SFN induced cell death in MCF-7 Cells via Apoptosis
To verify whether SFN induces apoptotic cell death
in MCF-7 cells, propidium iodide (PI) staining was
used to detect nuclear morphological changes. Results
show that MCF-7 cells treated with SFN for 24h had
undergone remarkable morphological changes such as
chromatin condensation and nuclear debris, which could
be identified as apoptotic bodies. On the other hand, the
nuclei of untreated cells intact and appeared uniform in
chromatin density (Figure 3). Thus, this study confirms
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Figure 4. Effect of Gemcitabine Treatment on MCF-7
Cells. Treatment of MCF-7 cells with varying concentrations
(0.1-100mM) of gemcitabine for 24 and 48h resulted in decrease
in cell viability in a dose and time dependent manner. The EC50
of gemcitabine was determined to be 35mM at 24h and 1mM at
48h. Values are means±SD of three independent experiments.
Each value with gemcitabine treatment differs from the control
value (p<0.05)

that SFN-treated cell death in MCF-7 cells is mediated
by apoptosis.
Lower dose combinations of SFN and gemcitabine may
act synergistically to suppress growth of MCF-7 cells
The combination effects were evaluated by selecting
two sub-lethal doses of both SFN and gemcitabine. The
sub-lethal doses of SFN i.e., 5μM and 10μM resulted in
17 and 24% decrease in cell viability (Figure 5). Similar
decrease in cell viability (34-39%) was also observed at
the sub-lethal doses of gemcitabine (5mM to 10mM).
Then, the effect of different combinations of SFN
and gemcitabine was evaluated. 5μM of SFN used in
combination with 5mM and 10mM gemcitabine resulted
in significant decrease in cell viability (54 and 65%
respectively) compared to either of the compounds alone.
Also, 10 μM sulforaphane when combined with 5mM
and 10mM gemcitabine resulted in significant decrease
in cell viability (56 and 58% respectively) in comparison
to the individual doses. The combination index (CI) was
calculated for all the combination and was found to be<1
thereby indicating a synergistic interaction of these drugs.
These results confirm the hypothesis that low doses of SFN
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resulted in decrease in COX-2 expression in MCF-7 cells
in a time dependant manner (Figure 6).
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Figure 5. Low-dose Combinations of SFN and
Gemcitabine Synergistically Induce Cell Death in
MCF-7 Cells. Simultaneous treatment of MCF-7 cells
with sub-lethal doses of SFN (S1=5µM and S2=10µM) and
gemcitabine (G1=5mM and G2=10mM) induced synergistic
decrease in cell viability of MCF-7 cells (combination index
[CI]<1). Each value is a ratio of the level in the treated cells to
that in the control cells. Values are means±SD of 3 independent
experiments. Each value with SFN and gemcitabine treatment
differs from the control value (p<0.05)
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Figure 6. SFN Downregulates the Expression of Bcl-2
and COX-2. 25µM SFN treatment significantly reduced the
expression of Bcl-2 and COX-2 in a time dependent manner in
MCF-7 cells compared to untreated cells. Lane 1 shows untreated
MCF-7 cells; lanes 2 and 3 show SFN treated MCF-7 cells for
6 and 24 h respectively; lane 4 shows negative control for RTPCR. β-actin was used as an internal control

can potentiate the effect of gemcitabine at lower doses.
SFN treatment downregulates the expression of Bcl-2
and COX-2
The effect of sulforaphane on the expression of
Bcl-2 (B-cell lymphoma), an anti-apoptotic gene, was
analyzed before and after treatment at various timepoints. Densitometric analysis of the transcript levels
was performed and normalized against β-Actin (Figure
6). Untreated MCF-7 cells showed high level of Bcl-2
expression indicative of evasion of apoptosis in these
cells. However, on treatment with SFN, its expression
was found to be significantly downregulated in in a time
dependant manner compared to the untreated control cells
(Figure 6). Thus SFN may induce apoptosis in these cells
by downregulating Bcl-2 gene.
Further, COX-2 expression was analysed in SFN
treated MCF-7 cells which has been shown to be involved
in inflammation and its upregulation has been reported in
various cancers. The untreated MCF-7 cells showed a high
level of expression of COX-2, whereas SFN treatment
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Efficacy of chemoprevention stems from the ability
of the dietary agents to counteract the various stages of
carcinogenesis that lead to DNA damage, generation of
free radicals and other forms of cellular stress. Therefore
it is coming up as an economical, easily available, and
novel approach to cancer treatment and management
(Karikas, 2010). Sulforaphane is an isothiocyanate, found
in cruciferous vegetables, such as broccoli, kale, and
cauliflower displays significant chemopreventive activity
resulting from its inhibition of carcinogen-activating
enzymes and induction of detoxification enzymes affecting
carcinogen metabolism and disposition and by modulating
epigenetic machinery (Barcelo et al., 1996; Basten et al.,
2002; Myzak et al., 2006; Gibbs et al., 2009).
In the present study, treatment with SFN at varying
concentrations resulted in dose and time-dependent
decrease in cell viability of MCF-7 cells. The effective
concentration (EC50) was found to be 25μM SFN for
duration of 24h (Figure 1). Other studies also showed
that SFN treatment significantly reduces cell viability
of various cancer cells i.e., human leukemia T-cells,
breast, pancreatic, lymphoblastoid and glioma cancer
cells in a dose-dependent manner (Fimognari et al., 2002;
Misiewicz et al., 2004; Meeran et al., 2010; Huang et
al., 2012; Li et al., 2012). Interestingly, SFN has a safe
cytotoxicity profile towards the normal cells thus it can
be utilized in the development of safe cancer treatment
strategies (Sharma et al., 2012).
Further, in order to evaluate whether the cytotoxic
effect of SFN on MCF-7 cells is via the apoptotic pathway,
microscopic examination and nuclear morphologic
analysis using propidium iodide were carried out.
Microscopic examination revealed that SFN treated cells
appeared rounded compared to the untreated MCF-7
cells indicative of apoptotic cell death (Figure 2). In
continuation, nuclear morphological analysis confirmed
that SFN induces apoptosis in these cells as SFN treated
cells showed the characteristic features of apoptosis such
as nuclear condensation and fragmentation as well as
formation of apoptotic bodies which accumulated in a
time-dependent manner (Figure 3). Hence, our results
confirm that decrease in MCF-7 cell viability by SFN
was due to its induction of apoptosis in these cells. These
results are in line with other studies which have also
shown that SFN induces cell death in cancer cells via
apoptosis (Kanematsu et al., 2011; Huang et al., 2012;
Li et al., 2012).
Apoptosis is a desirable mode of cell death by
different cancer treatment strategies and is regulated by
various genes such as Bcl-2, bax etc. The present study
investigated the effect of sulforaphane on expression of
the anti-apoptotic gene, Bcl-2, in MCF-7 cells by RT-PCR.
Our RT- PCR results showed the high expression of Bcl-2
in untreated MCF-7 cells which significantly decreased in
response to the sulforaphane treatment in time dependent
manner (Figure 6). These results are consistent with
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previous studies involving use of chemopreventive agents
to induce apoptosis by downregulation of Bcl-2 (PledgieTracy et al., 2007; Kalra et al., 2008; Kim et al., 2009;
Kumar et al., 2012). Considering that increased expression
of Bcl-2 may be related to chemoresistance, reduction in
the level of Bcl-2 by chemopreventive drugs such as SFN
may increase the sensitivity to anticancer drugs.
Gamut reports indicate that conventional cancer
treatment strategies have important but limited scope
as reflected in the poor life style of the cancer patients.
In this study, gemcitabine, a chemotherapeutic drug and
SFN were used in combination at lower doses. MCF-7
cells treated with gemcitabine alone showed a dose and
time-dependent decrease in cell viability (Figure 4). The
EC50 of gemcitabine on MCF-7 cells was found to be
35mM at 24h treatment. Various studies have also shown
its cytotoxicity towards various cancer cells (Pacini et al.,
1999; Strouch et al., 2009; Hastak et al., 2010). However,
it was found to have cytotoxic effects against normal
cells also (Sharma et al., 2011). Therefore, combinational
treatment modalities using conventional therapies such as
chemotherapy and newer strategies like chemoprevention
are gaining attention.
Our results on the combination of SFN and gemcitabine
show that SFN enhances the growth inhibitory effects of
gemcitabine at sub-lethal doses (Figure 5). When the
sub-lethal doses of SFN (5μM and 10μM) were used in
various combinations with lower doses of gemcitabine
(5mM and 10mM), the decrease in cell viability induced
by these combinations was more pronounced than either
of the compound alone and the CI index was found to
be<1 for each combination, thus indicating a synergistic
interaction between these drugs (Figure 5). This implies
that sulforaphane enhances the efficiency of gemcitabine
against the cancer cells, especially at lower doses, thereby
minimizing its cytotoxicity to normal cells resulting
in better survival. Other studies have also reported
a synergistic interaction between different treatment
strategies (Liu et al., 2001; Kuhar et al., 2007; Kumi-Diaka
et al., 2010; Wang et al., 2011). Other studies of concurrent
curcumin and chemotherapeutic drugs such as cisplatin,
doxorubicin, and taxol showed that curcumin enhances
the antitumor activities of the latter in various cancer cells
(Chan et al., 2003; Notarbartolo et al., 2005). SFN when
used in combination with arsenic trioxide and doxorubicin
augmented their growth inhibitory properties (Fimognari
et al., 2007; Doudican et al., 2012). Kotowski et al. (2011)
also found that SFN can induce radiosensitization in
head and neck cancer cells (Kotowski et al., 2011). Thus,
combining SFN with conventional treatment strategies
may allow minimizing their adverse effects.
Interestingly, a study on curcumin found that its
combination with celecoxib reduced the cell growth
in a synergistic manner which was in turn correlated
with the inhibition of COX-2 pathway (Lev-Ari et al.,
2005). Additionally it is well established that COX-2 is a
promising molecular target for cancer chemoprevention
owing to its involvement in inflammation (Khan et al.,
2012; Nadda et al., 2012). Based on these findings,
we analyzed the effect of SFN treatment on COX-2
expression in MCF-7 cells. The untreated MCF-7cells

showed a high level of expression of COX-2 while on SFN
treatment it was found to be significantly downregulated
in MCF-7 cells in a time dependant manner (Figure 6).
Several dietary components including curcumin, green
tea catechins, genistein etc have been shown to suppress
COX-2 expression (Plummer et al., 1999; Gerhäuser et
al., 2003; Hwang et al., 2009). Hence, it can be inferred
that reduction in COX-2 expression may be an important
target for chemoprevention by agents like SFN.
Conclusively, SFN exhibits anti-carcinogenic effects
and act as a biological response modifier in breast cancer
treatment. It can also be used in combination with
chemotherapeutic drugs to increase their efficacy and
reducing their side effects. Further comprehensive in vitro
and in vivo studies and clinical trials are requisite to make
SFN available for therapeutic purposes.
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